Skip to Main Content

Paper Details

DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition.
Cancer Discovery
13
2022
BRAF, DIPG, DIPGs, G469V, MAPK, MEK, MEK1/2, PDX models, children, dasatinib, patient, patient-, trametinib, trametinib-insensitive patient-derived cells
Author NameAffiliation
Elisa IzquierdoInstitute of Cancer Research
Diana CarvalhoInstitute of Cancer Research
Alan MackayInstitute of Cancer Research
Sara TemelsoInstitute of Cancer Research
Elisabet Fernández-RosasInstitute of Cancer Research
Valeria MolinariInstitute of Cancer Research
Matthew ClarkeInstitute of Cancer Research
Thomas S JacquesUCL Great Ormond Street Institute for Child Health
Lynley V MarshallDivision of Clinical Studies, The Institute of Cancer Research
Lynley V MarshallRoyal Marsden Hospital NHS Trust
Jacques GrillDepartment of Pediatric and Adolescent Oncology and INSERM Unit U, Team "Genomics and Oncogenesis of Pediatric Brain Tumors," Gustave Roussy and University Paris-Saclay
Maria VinciBambino Gesu Children's Hospital-IRCCS
Darren HargraveGreat Ormond Street Hospital for Children NHS Foundation Trust
Darren HargraveUCL Great Ormond Street Institute for Child Health
Chris JonesInstitute of Cancer Research
  • 1 - 15

Datasets

Release 1.2